UPADACITINIB (RINVOQ®)
Clinical Indication
Moderate to severe active rheumatoid arthritis, responded inadequately to, or who are intolerant to one or more DMARDs.
Comments
Not yet reviewed
Date of classification
February 2020
Review date
February 2020
Black
Drugs not recommended for use in the Leicestershire Health Community because of lack of evidence of clinical effectiveness, cost prioritization or concerns over safety.
All new drugs will be black until they have been through the appropriate approval process - then they will appear as a specific entry.